Publication:
A randomised controlled trial of the efficacy and safety of 0.25% desoximetasone cream (Topoxy) compared with 0.25% desoximetasone cream (Topicorte) for the treatment of scalp psoriasis

dc.contributor.authorLeena Chularojanamontrien_US
dc.contributor.authorNarumol Silpa-archaen_US
dc.contributor.authorPichanee Chaweekulraten_US
dc.contributor.authorChayanee Likitwattananuraken_US
dc.contributor.authorPuncharas Weerasubpongen_US
dc.contributor.authorNatchaya Junsuwanen_US
dc.contributor.authorNorramon Charoenpipatsinen_US
dc.contributor.authorChanisada Wongpraparuten_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.date.accessioned2020-10-05T05:42:45Z
dc.date.available2020-10-05T05:42:45Z
dc.date.issued2020-09-01en_US
dc.description.abstract© 2020 Faculty of Medicine Siriraj Hospital, Mahidol University. Objective: To compare the efficacy and safety of a generic desoximetasone cream (Topoxy) with the reference form, Topicorte, for the treatment of scalp psoriasis. Methods: A randomised, double-blind, controlled study was conducted. Altogether, 105 patients with psoriasis lesions covering more than 10% of the scalp were randomised into three groups. The first, second and third groups received a placebo, Topoxy and Topicorte, respectively. The scalp psoriasis severities were assessed at weeks 0, 2, 4 and 8, using the Investigator Global Assessment (IGA) scale and Total Sign Score (TSS). The safety profiles of the products were assessed by the patients and physicians. Results: Topoxy and Topicorte were significantly more effective than the placebo in achieving at least a two-grade improvement in the IGA score from baseline at weeks 2, 4 and 8, and there were no significant differences between Topoxy and Topicorte. The TSS of both creams were significantly lower than that of the placebo at weeks 2, 4 and 8. All patients tolerated well to the therapy. Conclusion: Topoxy and Topicorte had comparable efficacies for scalp psoriasis. The medications were superior to the placebo in all parameters, and had a good safety profile.en_US
dc.identifier.citationSiriraj Medical Journal. Vol.72, No.5 (2020), 371-379en_US
dc.identifier.doi10.33192/SMJ.2020.50en_US
dc.identifier.issn22288082en_US
dc.identifier.other2-s2.0-85089804291en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/59175
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089804291&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleA randomised controlled trial of the efficacy and safety of 0.25% desoximetasone cream (Topoxy) compared with 0.25% desoximetasone cream (Topicorte) for the treatment of scalp psoriasisen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089804291&origin=inwarden_US

Files

Collections